Superior Vena Cava Syndrome.
catheter-directed thrombolysis
endovascular therapy
superior vena cava obstruction
Journal
JACC. Cardiovascular interventions
ISSN: 1876-7605
Titre abrégé: JACC Cardiovasc Interv
Pays: United States
ID NLM: 101467004
Informations de publication
Date de publication:
28 12 2020
28 12 2020
Historique:
received:
16
06
2020
revised:
30
07
2020
accepted:
18
08
2020
entrez:
28
12
2020
pubmed:
29
12
2020
medline:
12
8
2021
Statut:
ppublish
Résumé
Superior vena cava (SVC) syndrome comprises a constellation of clinical signs and symptoms caused by obstruction of blood flow through the SVC. The management of patients with life-threatening SVC syndrome is evolving from radiation therapy to endovascular therapy as the first-line treatment. There is a paucity of data and societal guidelines with regard to the management of SVC syndrome. This paper aims to update the practicing interventionalists with the contemporary and the evolving therapeutic approach to SVC syndrome. In addition, the review will focus on endovascular techniques, including catheter-directed thrombolysis, angioplasty, and stenting, and their associated complications.
Identifiants
pubmed: 33357528
pii: S1936-8798(20)31972-5
doi: 10.1016/j.jcin.2020.08.038
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2896-2910Informations de copyright
Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Author Disclosures Dr. Rosenfield has served as a consultant for Abbott, Access Vascular, Accolade, Capture Vascular, Endospan, Magneto, Micell, Shockwave, Silk Road, Surmodics, Thrombolex, and Valcare; owns equity interest in Access Vascular, Contego, Embolitech, Eximo, MD Insider, Janacare, PQ Bypass, and Primacea; and has received research or fellowship support from National Institutes of Health. Dr. Bashir owns equity interest in Thrombolex Inc. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.